A carregar...
Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
We herein report the development and evaluation of a novel HER2-targeting antibody–drug conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our hydrophilic monodisperse polysarcosine (PSAR) drug-linker platform (PSARlink). In vitro and in vivo experiments were conducted in...
Na minha lista:
| Publicado no: | Pharmaceuticals (Basel) |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8000490/ https://ncbi.nlm.nih.gov/pubmed/33803327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14030247 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|